Theravance Biopharma, Inc.

TBPH

Theravance Biopharma, Inc.

TBPH

Insider Sentiment (TTM):

Last Purchase:2024-08-07Last Sale:2026-06-15Shares Purchased (TTM):0Shares Sold (TTM):149,949

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:47,722,536Shares Outstanding:51,279,000Institutional Ownership Pct.:93.06%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	220	288	168	175	282	111	38	23	46	54	40	72
Available For Sale Securities Debt Securities Curr…	168	107	148	155	57	20	51	68	50	46	63	62
Other Prepaid Expense Current	9	7	8	7	6	4	4	8	6	8	12	9
Assets Current	417	418	418	355	366	150	161	116	119	124	134	162
Available For Sale Securities Debt Securities Nonc…	-	-	11	3	-	-	-	-	-	-	-	-
Property Plant And Equipment Net	5	6	6	6	7	7	7	8	8	9	9	9
Operating Lease Right Of Use Asset	22	23	24	25	26	27	28	29	32	35	36	38
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	25	25	25	25	26	14	12	7	8	8	8	10
Assets	470	472	486	415	426	344	354	356	362	371	382	414
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	3	2	2	2	2	1	2	2	2	2
Employee Related Liabilities Current	8	9	13	10	7	5	7	8	6	4	6	7
Operating Lease Liability Current	11	11	11	11	11	11	11	4	4	4	4	10
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	-	0
Accrued Income Taxes Current	-	5	5	4	27	6	6	-	-	-	-	-
Other Accrued Liabilities Current	0	1	1	1	2	2	2	1	1	1	1	2
Liabilities Current	31	32	38	37	55	32	32	23	23	22	25	25
Operating Lease Liability Noncurrent	28	30	32	34	36	37	39	41	42	44	45	41
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Other Liabilities Noncurrent	0	0	0	0	2	1	2	5	5	5	6	8
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	-	-	-	-	-	0
Additional Paid In Capital	1,160	1,155	1,156	1,153	1,149	1,145	1,141	1,136	1,131	1,126	1,122	1,147
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	-	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-870	-865	-860	-921	-924	-979	-966	-950	-937	-921	-909	-901
Stockholders Equity	290	291	297	233	225	166	176	186	194	205	213	246
Liabilities And Stockholders Equity	470	472	486	415	426	344	354	356	362	371	382	414
Stockholders Equity Numbe…
Preferred Stock Number Of…
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Number Of Sh…
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	52	52	51	51	50	50	49	49	49	49	48	51
Shares Outstanding	52	52	51	51	50	50	49	49	49	49	48	51

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.64%	3.58%	-0.94%	-	-	-	-	-	-	-	-	-
2025	27.84%	26.70%	23.86%	12.32%	16.02%	18.04%	4.33%	2.08%	6.52%	16.81%	9.97%	12.81%
2024	-10.96%	-11.07%	-2.13%	7.42%	5.47%	11.33%	3.24%	-2.72%	-1.99%	-3.15%	2.31%	-2.41%
2023	-	-	-	-	-	-	5.76%	11.62%	-1.59%	-5.51%	-1.06%	-1.59%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	13.54	13.14	10.93	9.48	6.70	4.77	5.02	4.97	5.20	5.74	5.39	6.37
Quick Ratio	13.54	13.14	10.93	9.48	6.70	4.77	5.02	4.97	5.20	5.74	5.39	6.37
Working Capital	385.90M	385.86M	380.16M	317.29M	311.66M	118.76M	128.98M	93.05M	96.36M	102.63M	108.77M	136.32M
Leverage & Debt
Debt to Equity	0.11	0.11	0.13	0.16	0.24	0.19	0.18	0.13	0.12	0.11	0.12	0.10
Interest Coverage TTM	-24.08	-12.25	-11.06	-13.01	-14.42	-19.60	-18.44	-17.41	-16.73	-17.43	-23.84	-29.52
Debt Ratio	0.07	0.07	0.08	0.09	0.13	0.09	0.09	0.07	0.06	0.06	0.06	0.06
Efficiency & Turnover
Asset Turnover TTM	0.23	0.27	0.26	0.21	0.20	0.18	0.17	0.16	0.15	0.14	0.12	0.09
Per Share Metrics
Diluted EPS TTM	1.04	2.23	2.06	0.57	0.26	-1.17	-1.15	-1.01	-0.94	-0.93	-1.00	-1.09
Free Cash Flow Per Share TTM	1.04	5.24	4.74	4.82	4.88	0.65	-0.24	-0.25	-0.20	-0.38	-0.53	-2.91
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	-	103.95%	104.09%	104.18%
Operating Profit Margin TTM	-26.67%	-20.28%	-25.33%	-40.85%	-48.18%	-76.88%	-72.92%	-69.61%	-67.58%	-68.82%	-97.58%	-123.33%
Net Profit Margin TTM	51.58%	104.34%	98.54%	36.53%	16.88%	-89.38%	-87.63%	-78.18%	-73.61%	-72.78%	-96.11%	-104.65%
Growth Metrics
Net Revenue Growth (1Y)	35.11%	68.20%	66.92%	27.12%	24.49%	6.11%	12.12%	15.93%	20.97%	26.65%	11.84%	5.55%
Net Income Growth (1Y)	312.92%	-296.36%	-287.70%	-159.40%	-128.54%	30.30%	2.22%	-13.40%	-105.26%	-105.11%	-106.33%	-106.71%
EPS Growth (1Y)	301.01%	-290.33%	-282.21%	-157.66%	-127.73%	26.57%	15.73%	-7.53%	-106.11%	-106.66%	-108.42%	-109.67%
Valuation Metrics
P/E TTM	16.32	7.27	8.89	25.14	42.47	-7.61	-8.15	-8.00	-9.05	-9.67	-11.26	-7.92
P/B TTM	3.03	2.86	3.17	3.17	2.46	2.67	2.62	2.13	2.13	2.11	2.92	1.84
P/S TTM	8.42	7.58	8.76	9.18	7.17	6.80	7.14	6.25	6.67	7.04	10.82	8.29
Market Cap	878.34M	832.26M	941.43M	737.59M	553.45M	443.87M	459.65M	395.25M	413.37M	433.10M	621.61M	451.88M
Enterprise Value	657.74M	543.32M	772.79M	561.98M	270.69M	332.42M	421.02M	371.03M	366.19M	378.43M	581.22M	379.35M
Calculated Values
Free Cash Flow TTM	53.73M	268.74M	238.50M	243.48M	244.78M	32.19M	-11.96M	-12.40M	-9.69M	-18.44M	-29.49M	-152.28M
Net Debt	-220.60M	-288.94M	-168.64M	-175.61M	-282.76M	-111.45M	-38.63M	-24.21M	-47.18M	-54.67M	-40.38M	-72.52M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-15Sale

Owner: Farnum, Rhonda

Title: SVP, COMM & MEDICAL AFFAIRS

Shares: 13,314

Price/Share: $16.39

Value: $218,216.46

Shares Owned: 232,457

Relationship: Officer

Ownership: Direct

2026-03-16Sale

Owner: Farnum, Rhonda

Title: SVP, COMM & MEDICAL AFFAIRS

Shares: 31,067

Price/Share: $13.95

Value: $433,384.65

Shares Owned: 232,699

Relationship: Officer

Ownership: Direct

2025-12-03Sale

Owner: Farnum, Rhonda

Title: SVP, COMM & MEDICAL AFFAIRS

Shares: 31,067

Price/Share: $18.75

Value: $582,506.25

Shares Owned: 277,695

Relationship: Officer

Ownership: Direct

2025-11-26Sale

Owner: Broshy, Eran

Title: -

Shares: 29,501

Price/Share: $20.00

Value: $590,020.00

Shares Owned: 44,703

Relationship: Director

Ownership: Direct

2025-11-11Sale

Owner: Broshy, Eran

Title: -

Shares: 45,000

Price/Share: $18.00

Value: $810,000.00

Shares Owned: 60,204

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-15	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	13,314	16.39	$218,216.46	232,457	4
2026-03-16	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	31,067	13.95	$433,384.65	232,699	4
2025-12-03	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	31,067	18.75	$582,506.25	277,695	4
2025-11-26	Broshy, Eran	Director	-	Direct	Sale	29,501	20.00	$590,020.00	44,703	4
2025-11-11	Broshy, Eran	Director	-	Direct	Sale	45,000	18.00	$810,000.00	60,204	4/A
2025-07-14	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	10,000	11.39	$113,900.00	326,918	4
2025-06-02	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	24,000	11.00	$264,000.00	336,918	4
2025-04-21	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	4,000	9.00	$36,000.00	370,038	4
2025-01-21	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	4,000	9.00	$36,000.00	309,565	4
2024-11-11	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	4,000	9.00	$36,000.00	322,743	4
2024-08-07	Samaha, Eli	TenPercentOwner	-	Indirect	Purchase	999,800	7.80	$7,798,440.00	9,511,150	4
2024-07-10	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	4,000	9.00	$36,000.00	335,965	4
2024-05-01	Samaha, Eli	TenPercentOwner	-	Indirect	Purchase	1,499,124	8.75	$13,117,335.00	8,511,350	4
2024-02-22	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	1,254	8.71	$10,922.34	311,733	4
2023-11-21	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	1,378	10.29	$14,179.62	331,206	4
2023-11-14	Graham, Richard A	Officer	SVP, RESEARCH & DEVELOPMENT	Direct	Sale	2,482	10.22	$25,366.04	346,839	4
2023-10-16	Graham, Richard A	Officer	SVP, RESEARCH & DEVELOPMENT	Direct	Sale	2,482	9.03	$22,412.46	334,321	4
2023-09-14	Graham, Richard A	Officer	SVP, RESEARCH & DEVELOPMENT	Direct	Sale	2,482	9.89	$24,546.98	336,803	4
2023-08-22	Farnum, Rhonda	Officer	SVP, COMM & MEDICAL AFFAIRS	Direct	Sale	1,807	9.47	$17,112.29	340,566	4
2023-08-11	Graham, Richard A	Officer	SVP, RESEARCH & DEVELOPMENT	Direct	Sale	2,322	9.99	$23,196.78	349,746	4
2023-07-14	Graham, Richard A	Officer	SVP, RESEARCH & DEVELOPMENT	Direct	Sale	2,322	9.84	$22,848.48	352,068	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

93.06%

Inst. Shares: 47,722,536

Shares Outstanding: 51,279,000

2025-12-31

94.37%

Inst. Shares: 47,483,655

Shares Outstanding: 50,317,000

2025-09-30

92.71%

Inst. Shares: 46,837,011

Shares Outstanding: 50,520,000

2025-06-30

90.72%

Inst. Shares: 45,520,042

Shares Outstanding: 50,177,000

2025-03-31

88.84%

Inst. Shares: 44,156,950

Shares Outstanding: 49,706,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	47,722,536	51,279,000	93.06%
2025-12-31	47,483,655	50,317,000	94.37%
2025-09-30	46,837,011	50,520,000	92.71%
2025-06-30	45,520,042	50,177,000	90.72%
2025-03-31	44,156,950	49,706,000	88.84%
2024-12-31	43,340,185	48,847,000	88.73%
2024-09-30	43,977,755	49,038,000	89.68%
2024-06-30	41,035,981	48,747,000	84.18%
2024-03-31	39,623,015	48,283,000	82.06%
2023-12-31	40,851,481	55,303,000	73.87%
2023-09-30	42,332,466	52,361,000	80.85%
2023-06-30	44,063,328	56,682,000	77.74%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Theravance Biopharma, Inc. (TBPH) — SEC Financial Statements & Analysis

Theravance Biopharma, Inc. (TBPH) is a pharmaceutical preparations company, incorporated in CA. Theravance Biopharma, Inc. trades on Nasdaq as: TBPH. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Theravance Biopharma, Inc. reported a 35.11% year-over-year revenue growth, a Gross Profit Margin of 103.95% (TTM), a Debt-to-Equity ratio of 0.11x, a Price-to-Sales (P/S) ratio of 8.42x (TTM), a Price-to-Book (P/B) ratio of 3.03x (TTM), at a market cap of $878.34M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 35.11%
Gross Profit Margin TTM: 103.95%
Debt To Equity: 0.11x
P/S TTM: 8.42x
P/B TTM: 3.03x
Market Cap: $878.34M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Theravance Biopharma, Inc. in?

Theravance Biopharma, Inc. (TBPH) operates in the Pharmaceutical Preparations industry.

What is TBPH's market cap?

Theravance Biopharma, Inc. (TBPH) has a market capitalization of $878.34M as of 2026-06-30.

What is TBPH's P/E ratio?

Theravance Biopharma, Inc. (TBPH)'s trailing twelve month P/E ratio is 16.32x as of 2026-06-30.

What exchange does TBPH trade on?

Theravance Biopharma, Inc. (TBPH) trades on the Nasdaq.

Where is Theravance Biopharma, Inc. incorporated?

Theravance Biopharma, Inc. is incorporated in CA.